Chapman Steven Leonard sold $819K of NTRA

Chapman Steven Leonard (CEO AND PRESIDENT) sold 3,076 shares of Natera, Inc. (NTRA) at an average of $266.40 ($259.98–$268.22, $0.82M total) across 7 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chapman Steven Leonard
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
medium confidence
Mentioned
$NTRA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The disclosure updates the record of insider activity, but the pre-arranged 10b5-1 structure reduces the likelihood of a new fundamental narrative.

02

Market read

Traders may monitor insider activity for sentiment, but this specific filing is unlikely to drive a durable repricing without additional company news.

03

What to watch

The article does not state whether the CEO increased other holdings, sold for tax/option exercises, or whether there were concurrent company-specific catalysts; without that, the trading signal is weak.

Relevance 4/10Novelty 4/10Timing: filed Aug 5, covering sales executed Aug 3

Background

This is an SEC Form 4 insider transaction for Natera, Inc., reported by the CEO and President.

Company-level read

Ticker impact

$NTRANeutralMedium confidence
Context

Natera CEO and President Chapman Steven Leonard sold about $819K of NTRA shares via an open-market sale under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

Form 4 shows a scheduled 10b5-1 sale (not a surprise discretionary sale) and provides no accompanying operational or guidance change.

Market effects

Minimal; insider selling in a single biotech/diagnostics name does not reset sector fundamentals.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity rather than bearish expectations, so any negative read-through could be overdone.

Key entities

  • Natera, Inc.

    Company whose CEO and President reported an open-market sale of shares on a 10b5-1 plan.

  • Chapman Steven Leonard

    CEO and President who sold 3,076 shares across seven trades on Aug 3, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.